Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

MARIN, DAVID

One or more keywords matched the following items that are connected to MARIN, DAVID

Item Type	Name
Concept	Piperazines
Academic Article	Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Academic Article	The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Academic Article	Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Academic Article	Clinical decisions for chronic myeloid leukemia in the imatinib era.
Academic Article	Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Academic Article	Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
Academic Article	Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Academic Article	Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Academic Article	Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Academic Article	Management decisions in chronic myeloid leukemia.
Academic Article	Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Academic Article	Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.
Academic Article	Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Academic Article	Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Academic Article	The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Academic Article	Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Academic Article	Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Academic Article	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Academic Article	EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Academic Article	KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Academic Article	Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Academic Article	Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article	Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Academic Article	Management of the new patient with CML in chronic phase.
Academic Article	Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
Academic Article	Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Academic Article	Imatinib or transplant for chronic myeloid leukaemia?
Academic Article	Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
Academic Article	Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
Academic Article	Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment.
Academic Article	Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Academic Article	European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Academic Article	Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
Academic Article	The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.
Academic Article	Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Academic Article	Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.
Academic Article	hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Academic Article	Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.
Academic Article	Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Academic Article	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Academic Article	Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article	Is imatinib still an acceptable first-line treatment for CML in chronic phase?
Academic Article	A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
Academic Article	Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons.
Academic Article	In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Academic Article	Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Academic Article	Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
Academic Article	Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
Academic Article	Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Academic Article	Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
Academic Article	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Academic Article	Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Academic Article	Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.
Academic Article	PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.

Search Criteria

Piperazines